A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance

Pancreatic cancer is predominantly lethal, and is primarily treated using gemcitabine, with increasing resistance. Therefore, novel agents that increase tumor sensitivity to gemcitabine are needed. Histone deacetylase (HDAC) inhibitors are emerging therapeutic agents, since HDAC plays an important r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hee Seung, Park, Soo Been, Kim, Sun A, Kwon, Sool Ki, Cha, Hyunju, Lee, Do Young, Ro, Seonggu, Cho, Joong Myung, Song, Si Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278546/
https://www.ncbi.nlm.nih.gov/pubmed/28134290
http://dx.doi.org/10.1038/srep41615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278546/
https://www.ncbi.nlm.nih.gov/pubmed/28134290
http://dx.doi.org/10.1038/srep41615

Ejemplares similares